NCT07263191Recruiting
A Study of Olanzapine in Participants With Bipolar Disorder.
A Multicenter, Prospective Observational Study to Evaluate Treatment Patterns and Safety in Patients With Bipolar Disorder Taking Olanzapine
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 23 Nov 2025
- Start date
- 30 Oct 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Diseases
- Bipolar disorder
- NCT number
- NCT07263191
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 30 Oct 2025 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
Other
- Female patients who are pregnant, have childbearing potential, or are breastfeeding.
- Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Who the study is looking for
- Patients who have signed the informed consent after receiving information about the purpose and method of this study.
- Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
- Patients who understand the contents of the survey and can answer the questions directly.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHA Bundang Medical Center Coordinator of this site? Confirm its status | Seongnam | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.